offline
Healthcare | Biotechnology | USA
Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition
Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.
...
Shares of Sarepta Therapeutics (SRPT - Get Report) surged nearly 10% on Wednesday after the company announced an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy showed promising results.
...
Sarepta's early stage study and trial of its MYO-101 treatment showed a benefit for patients with a lesser-known, severe form of muscular dystrophy that primarily affects shoulders and hips.
...
https://www.thestreet.com/investing/stoc...l-14880311
![[Bild: SRPTc1dl1212.png]](https://finviz.com/publish/022719/SRPTc1dl1212.png)
Sarepta Shares Surge on Positive Muscular Dystrophy Trial, Myonexus Acquisition
Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.
...
Shares of Sarepta Therapeutics (SRPT - Get Report) surged nearly 10% on Wednesday after the company announced an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy showed promising results.
...
Sarepta's early stage study and trial of its MYO-101 treatment showed a benefit for patients with a lesser-known, severe form of muscular dystrophy that primarily affects shoulders and hips.
...
https://www.thestreet.com/investing/stoc...l-14880311
